NCT00023712 2019-07-30
Bortezomib in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer
National Cancer Institute (NCI)
Phase 2 Completed
Clinical Trials
3 trialsNCT00610792 2009-07-14
Phase 2 Study of Twice Weekly VELCADE and CAELYX in Patients With Ovarian Cancer Failing Platinum Containing Regimens
Millennium Pharmaceuticals, Inc.
Phase 2 Withdrawn
NCT00106262 2007-04-18
Study of Velcade and Irinotecan in Advanced Cervical, Vulvar, or Vaginal Cancer
Women and Infants Hospital of Rhode Island
Phase 2 Terminated